CONy 2023 | Stopping clinical therapy trials because of futility: should it be allowed?

Amos Korczyn, MD, Tel Aviv University, Tev Aviv, Israel, discusses whether it should be allowed to stop clinical trials because of futility, meaning the primary efficacy endpoints are unlikely to be achieved. This approach is being increasingly used in clinical trials and can, at times, be motivated by financial and/or ethical considerations. Futility stopping has boosted debates among clinicians and patients, mainly because of ethical reasons. While there are no clear answers to this controversy, Prof. Korczyn believes this topic should continue to be discussed. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.